Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly Chin

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The European Respiratory Journal|August 19, 2017
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertensionSean Gaine, Kelly Chin, Gerry Coghlan, et al.
JACC. Advances|February 25, 2025
Outcomes in Patients Receiving Treatment for Pulmonary Arterial Hypertension Associated With Repaired Congenital Heart DiseaseRichard A Krasuski, Tobore Tobore, Sean Studer, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 8, 2018
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON StudyJ Gerry Coghlan, Richard Channick, Kelly Chin, et al.
Annals of the American Thoracic Society|April 14, 2026
Biological Sex Differences in the US-CTEPH-RMeghan M Cirulis, William R Auger, Raymond L Benza, et al.
Pulmonary Circulation|June 13, 2024
Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studiesAllan Lawrie, Kelly Chin, Yiu-Lian Fong, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI<sub>2</sub>) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) studyIoana R Preston, Richard N Channick, Kelly Chin, et al.
Pulmonary Circulation|November 18, 2021
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertensionRobert P Frantz, Raymond L Benza, Richard N Channick, et al.
Chest|June 6, 2021
Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-upKim M Kerr, C Greg Elliott, Kelly Chin, et al.
Pulmonary Circulation|December 19, 2017
The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking studyTakahiro Sato, Bharath Ambale-Venkatesh, Joao A C Lima, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2015
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial HypertensionPaul M Hassoun, Roham T Zamanian, Rachel Damico, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The European Respiratory Journal|August 19, 2017
Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertensionSean Gaine, Kelly Chin, Gerry Coghlan, et al.
JACC. Advances|February 25, 2025
Outcomes in Patients Receiving Treatment for Pulmonary Arterial Hypertension Associated With Repaired Congenital Heart DiseaseRichard A Krasuski, Tobore Tobore, Sean Studer, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 8, 2018
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON StudyJ Gerry Coghlan, Richard Channick, Kelly Chin, et al.
Annals of the American Thoracic Society|April 14, 2026
Biological Sex Differences in the US-CTEPH-RMeghan M Cirulis, William R Auger, Raymond L Benza, et al.
Pulmonary Circulation|June 13, 2024
Two prospective, multicenter studies for the identification of biomarker signatures for early detection of pulmonary hypertension (PH): The CIPHER and CIPHER-MRI studiesAllan Lawrie, Kelly Chin, Yiu-Lian Fong, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 4, 2017
Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI<sub>2</sub>) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) studyIoana R Preston, Richard N Channick, Kelly Chin, et al.
Pulmonary Circulation|November 18, 2021
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertensionRobert P Frantz, Raymond L Benza, Richard N Channick, et al.
Chest|June 6, 2021
Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-upKim M Kerr, C Greg Elliott, Kelly Chin, et al.
Pulmonary Circulation|December 19, 2017
The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking studyTakahiro Sato, Bharath Ambale-Venkatesh, Joao A C Lima, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2015
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial HypertensionPaul M Hassoun, Roham T Zamanian, Rachel Damico, et al.
Pageof 3